Cleo signed a collaboration agreement with University College London which gives them access for a clinical study to over 2000 high quality samples.
Advantages- there will not be any long waiting time as no recruitment of patients needed as samples are already available, hence FAST TRACK.
UKCTOS have granted access to these samples as the previous years of testing using the current and outdated/limited CA125 and ultra sound found that these existing tools can’t be recommended as a screening tool today.
Cleo now have a great opportunity to create an FDA compliant diagnostic kit, addressing a critical need since ovarian cancer is often diagnosed late.
All in all it’s a positive step forward the company and shareholders.
DYOR
COV Price at posting:
40.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)